Current approaches attempt to modulate the immune response by targeting specific cytokine pathways.
Unfortunately, this can lead to immunosuppression, increasing the risk of serious infections and malignancy, especially considering the need for long-term use.
Targeted modulation of the T-cell receptor (TCR) activation forms the core of everything we do at Artax Biopharma. We develop medicines that act to specifically block Nck recruitment upon TCR activation, preventing inappropriate activation by self-antigens — and therefore without causing immunosuppression.
Completed in 2023